Eli Lilly's GLP-1 Juggernaut Powers 48% Revenue Jump, Eyes Next Obesity Blockbuster

Lilly's GLP-1 Dominance Drives $23 Billion Quarter

Eli Lilly reported second-quarter revenue of $23 billion, a 48% surge from a year earlier, driven overwhelmingly by its two blockbuster GLP-1 drugs. Mounjaro, approved for type 2 diabetes, generated $9.9 billion—up 91%—while Zepbound, the weight-management counterpart, added $5 billion in sales, a 46% increase. Together they accounted for more than half of the company’s top line.

The Indianapolis-based pharma giant continues to extend its lead over Danish rival Novo Nordisk in the fiercely contested obesity and diabetes market. CFO Lucas Montarce told analysts that Lilly products captured an estimated 60% to 70% of all new GLP-1 prescriptions in the United States during the quarter, cementing a shift in market share that began last year.

A new weapon in Lilly’s arsenal is Foundayo, an oral GLP-1 pill that launched in April and just began broad direct-to-consumer advertising. The campaign emphasises that Foundayo can be taken at any time of day without restrictions on food or drink—a direct counter to Novo Nordisk’s injectable-free Wegovy pill. In its first partial quarter, Foundayo recorded $98 million in sales, a figure expected to grow rapidly as consumer awareness builds.

Looking ahead, Lilly is pinning its next growth phase on retatrutide, a triple-hormone receptor agonist now in late-stage clinical trials. Chief Scientific Officer Dan Skovronsky noted that retatrutide has produced “a magnitude of weight loss not previously seen” in patients with diabetes and obesity. The company aims to submit the drug for FDA approval next year. Separately, reports of a special-access request for a 79-year-old patient—which briefly sparked speculation about former President Donald Trump—were denied by the White House, but the episode has thrust Lilly’s pipeline into the political spotlight.

Behind Lilly's Obesity Drug Lead and What Comes Next

Mounjaro and Zepbound: A Widening Moat

Lilly’s 91% year-over-year jump in Mounjaro sales reflects both expanding use in diabetes and rising off-label adoption for weight loss, while Zepbound’s 46% growth underscores the still-insatiable demand for medically managed obesity. The two drugs are not interchangeable; Zepbound carries a dedicated obesity indication that gives it favourable insurance coverage dynamics. With Lilly now commanding roughly two-thirds of new GLP-1 prescriptions, the commercial momentum is self-reinforcing: more physician familiarity, broader payer contracts, and a growing base of patient success stories that anchor loyalty.

Foundayo: An Oral Counter Punch to Wegovy Pill

The Foundayo launch is strategically timed. Novo Nordisk’s high-dose semaglutide pill for weight loss has been touted as a game-changer for needle-averse patients, but it requires taking on an empty stomach with specific timing. Foundayo eliminates those inconveniences, a message DTC ads are already hammering home. The $98 million in early sales may look small next to injectable billions, but if the consumer positioning sticks, Foundayo could capture a large slice of the millions of Americans who prefer a daily pill over a weekly injection. For Novo Nordisk, this adds a new front in the battle just as its own oral franchise tries to gain traction.

Retatrutide and the “Trump Access” Episode

Retatrutide is the real wildcard. While it still faces FDA scrutiny, a “triple agonist” mechanism that targets GLP-1, GIP and glucagon receptors could raise the ceiling on weight loss efficacy significantly. The early-access programme for select patients—revealed before phase 3 data were fully public—is unusual and suggests Lilly is confident enough to manage carefully controlled pre-approval use. The unrelated Trump speculation, though denied, has already drawn political attention to the drug. Reputational risk is limited, but with obesity drugs becoming a national talking point, any link between a pipeline therapy and a former president will be watched closely by regulators and the public.

Guidance Lift and What It Signals

Lilly raised its full-year 2026 revenue forecast to $85–$87 billion, up from $82–$85 billion. That $3 billion bump, just months into the year, signals that management expects the GLP-1 wave to keep building. The figures also suggest that supply constraints are easing. For investors, the guidance implies that demand is not anywhere near peaking, and that Lilly’s manufacturing scale—a historical bottleneck for many biologics—is finally catching up.

Strategic Moves for Investors and Competitors in the GLP-1 Race

• Investors: Track retatrutide’s phase 3 completion schedule and any FDA submission announcement—likely a major share price catalyst. Because Lilly’s current valuation already bakes in strong GLP-1 growth, the real upside from here may hinge on that next asset’s approval and differentiated efficacy.
• Competitors (Novo Nordisk and challengers): Foundayo’s DTC push directly attacks the convenience pain point of existing oral GLP-1s. Rivals must either match the “any-time, no-food-planning” claim or find another edge; waiting for next-generation molecules is risky when Lilly is already converting patients at this pace.
• Payers and employers: With two oral GLP-1 options now actively marketed, expect a surge in formulary requests and prior-authorization volume. Plan sponsors should prepare utilization management rules specifically for Foundayo vs. Wegovy pill, factoring in patient preference and actual adherence data.
• Observers of the Trump speculation: The White House denial likely closes the immediate story, but any future revelations about special access for high-profile individuals could trigger Congressional scrutiny. Companies may need to tighten their compassionate-use protocols to avoid reputational fallout.